Trial Profile
Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 May 2022
Price :
$35
*
At a glance
- Drugs Piflufolastat F18 (Primary)
- Indications Prostate cancer
- Focus Diagnostic use
- 06 May 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2022.
- 06 May 2022 Status changed from recruiting to active, no longer recruiting.
- 12 Jan 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2022.